Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...
Fortress Biotech, Inc. (NASDAQ: FBIO) announced through its majority-controlled subsidiary, Journey Medical Corporation, that the U.S. Food and Drug Administration (FDA) has approved Emrosiâ„¢ ...
“You’re sharing your trauma journey ... was not using the drug to treat a mental health problem, Ghaemi said many are seeking ...
The FDA approved Emrosi (minocycline hydrochloride extended-release capsules) for the treatment of inflammatory lesions of rosacea in adults.
Journey Medical's new rosacea treatment will rival industry giant Galderma's Oracea in the treatment of rosacea.
Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...
Key trial focus: PK/PD in healthy subjects, with PK bracketed by standard epinephrine injections No placebo-controlled efficacy studies required NORTH HAVEN, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ...
Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care ...
As demand for popular weight-loss drugs like Wegovy and Zepbound skyrockets, patients are taking dosage amounts into their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback